AGAP2 and breast carcinoma: For instance, trastuzumab resistance has been reported in breast cancer by AGAP2-AS1 and SNHG14 [62,63], whereas UCA1 was responsible for tamoxifen resistance in breast cancer [64], cisplatin resistance in ovarian cancer [65], and cetuximab resistance in metastatic colorectal cancer [66].